GridAI Technologies Corp.

For the period ended Dec 31, 2024. Filed Apr 1, 2025.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Apr 1, 2025

GRDX$5.35+8.7%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Signatures

In accordance with Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, there unto duly authorized.


	FIRST WAVE BIOPHARMA, INC.

April 1, 2025
	By:	/s/ Richard Paolone
		Name: Richard Paolone
		Title: Interim Chief Executive Officer

	By:	/s/ Anna Skowron
		Name: Anna Skowron
		Title: Interim Chief Financial Officer

Pursuant to the requirements of the Securities Exchange Act of 1934, this Report has been signed by the following persons on behalf of the registrant and in the capacities held on the dates indicated.

Signature	Title	Date

/s/ Richad Paolone	Interim Chief Executive Officer and Director	April 1, 2025
Richard Paolone	(principal executive officer)

/s/ Anna Skowron	Interim Chief Financial Officer	April 1, 2025
Anna Skowron	(principal financial officer and accounting officer)

/s/ Edward J. Borkowski	Director	April 1, 2025
Edward J. Borkowski

/s/ Eric G. Corbett	Director	April 1, 2025
Eric G. Corbett

/s/ Manpreet Uppal	Director	April 1, 2025
Manpreet Uppal

/s/ Jack Syage	Director	April 1, 2025
Jack Syage

-83-

** Entero Therapeutics, Inc.**

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.